Welcome to our dedicated page for NGM Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on NGM Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative, life-changing medicines. With a strong focus on cardio-metabolic and liver diseases, NGM Bio leverages its cutting-edge drug discovery platform to generate a pipeline of first-in-class biologic drug candidates, targeting a wide range of disease areas, including cancer.
NGM Bio's approach is deeply rooted in understanding the biology of hormones, cell receptors, and associated ligands. By investigating these biological mechanisms, the company assembles a comprehensive understanding of protein structure-function relationships. This approach, combined with expertise in protein and antibody engineering, allows NGM Bio to create potential first-in-class therapeutics with optimized pharmacologic profiles efficiently.
On the financial front, NGM Bio reported significant progress in 2023. The company continues to advance its clinical-stage solid tumor oncology portfolio with promising results. Additionally, NGM Bio's ALPINE 4 trial for aldafermin, targeting patients with compensated cirrhosis due to NASH, achieved its primary endpoint with positive results. This indicates clinical impact in a challenging patient population and positions aldafermin for potential late-stage development partnerships.
NGM Bio has also made strides in developing NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab). This combination has shown encouraging responses in heavily pretreated patients with advanced disease, including MSS CRC, which is typically unresponsive to anti-PD-1/L1 monotherapy.
In January 2024, NGM Bio announced its strategy to further focus its development efforts on rare conditions with significant unmet needs, such as Primary Sclerosing Cholangitis (PSC) and Hyperemesis Gravidarum (HG). This strategic shift aims to maximize near-term impact and value creation while staying aligned with NGM Bio's mission to deliver transformative medicines for patients.
Moreover, NGM Bio has entered into a definitive Agreement and Plan of Merger with Atlas Neon Parent, Inc., under which all outstanding shares of NGM Bio will be acquired at a price of $1.55 per share in cash. This acquisition is expected to close in the second quarter of 2024, resulting in NGM Bio becoming a privately held company.
Overall, NGM Biopharmaceuticals, Inc. is at the forefront of ushering in new therapeutic options for various diseases, driven by a robust research pipeline and strategic collaborations. For more information, visit NGM Bio's website.
NGM Biopharmaceuticals, Inc. (NGM) has priced an underwritten public offering of 4,629,630 shares of its common stock at $27.00 per share, aiming for approximately $125 million in gross proceeds. The offering is set to close on or about January 8, 2021, pending customary conditions. There is a 30-day option for underwriters to purchase an additional 694,444 shares. Goldman Sachs, Citigroup, and Cowen are joint book-running managers, with Raymond James and B. Riley Securities as lead managers. The offering is registered under an effective shelf registration statement with the SEC.
NGM Biopharmaceuticals, Inc. (NGM) has announced a public offering of $100 million in common stock, with an additional $15 million option for underwriters. All shares will be sold by NGM, which is subject to market conditions. Goldman Sachs, Citigroup, and Cowen are managing the offering. The shares will be offered under a previously filed shelf registration statement with the SEC. NGM focuses on developing therapeutics for liver diseases, metabolic disorders, retinal diseases, and cancer.
NGM Biopharmaceuticals has introduced NGM438, a new antibody candidate targeting LAIR1, during its inaugural R&D Day. LAIR1 is implicated in tumor-associated immune suppression. The company aims to initiate first-in-human trials for NGM438 in Q4 2021. NGM438 is designed to enhance anti-tumor immunity by disrupting LAIR1-collagen interactions, which may improve responses to current immunotherapies. Alongside NGM438, NGM707 and NGM120 are part of its oncology pipeline, focusing on reversing immune suppression.
NGM Biopharmaceuticals will host a virtual R&D Day on December 9, 2020 at 12:00 pm ET, showcasing its multi-therapeutic pipeline. The event will highlight key drug candidates addressing unmet patient needs in liver and metabolic diseases, retinal diseases, and cancer, including aldafermin and MK-3655, NGM621, NGM120, and NGM707. Notable speakers include distinguished industry physicians and executives from Merck. The event will be streamed live, with a replay available on the NGM website for one year.
NGM Biopharmaceuticals reported positive results from its Phase 1 study of NGM621, an anti-complement C3 antibody for geographic atrophy. The treatment showed a favorable safety profile, with no serious adverse events or intraocular inflammation. The serum pharmacokinetics were linear and dose-proportional, supporting a potential dosing regimen of every eight weeks. The ongoing Phase 2 CATALINA study has begun enrollment, with the first patient dosed in July 2020. NGM621 may offer significant advantages in treating this progressive retinal disease.
NGM Biopharmaceuticals (NGM) reported significant advances in its therapeutic pipeline as of September 30, 2020. The company initiated a Phase 2 clinical trial for NGM621 targeting geographic atrophy and expanded its oncology portfolio with NGM707, an immuno-oncology candidate. Financially, NGM reported a net loss of $29.8 million, up from $10.9 million in 2019, while research and development expenses surged to $47 million. NGM's cash reserves stood at $287.9 million, down from $344.5 million at year-end 2019, emphasizing ongoing investments in its expanding pipeline.
NGM Biopharmaceuticals (NGM) announced that CEO David J. Woodhouse, Ph.D., will present at three investor conferences. The presentations are scheduled for:
- November 18, 2020: Jefferies Virtual London Healthcare Conference at 12:00 PM ET
- November 18, 2020: Stifel Virtual Healthcare Conference at 2:40 PM ET
- November 23, 2020: 32nd Annual Piper Sandler Virtual Healthcare Conference at 12:00 PM ET
A live webcast will be available on the NGM website, and a replay of the presentation will be archived for 90 days.
NGM Biopharmaceuticals announced the upcoming poster presentation of its Phase 1 study on NGM621, a monoclonal antibody targeting complement C3, at the American Academy of Ophthalmology (AAO) 2020 Virtual event. The study focuses on its safety, tolerability, and pharmacokinetics in patients with geographic atrophy (GA). The presentation is scheduled for Nov. 13, 2020. NGM621 is engineered for potential extended dosing and aims to address issues arising from complement system dysregulation. The company is committed to advancing innovative therapeutics in retinal diseases and other conditions.
NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) announced multiple presentations of aldafermin at AASLD’s The Liver Meeting, scheduled for Nov. 13-16, 2020. A late-breaking oral presentation will showcase results from the 24-week Phase 2 study on aldafermin in patients with non-alcoholic steatohepatitis (NASH). The study's findings indicate significant anti-fibrotic responses in patients with advanced fibrosis. Additional presentations will cover lipid management and improvements in non-invasive measures related to NASH. Aldafermin aims to address liver disease by targeting multiple pathways, demonstrating promising clinical efficacy.
NGM Biopharmaceuticals (NGM) announced the expansion of its oncology portfolio with NGM707, a novel dual antagonist antibody targeting ILT2 and ILT4, which may enhance anti-tumor immune responses. First-in-human testing is planned for mid-2021. NGM707 aims to combat myeloid cell immune suppression implicated in immune evasion by tumors. This new candidate complements NGM120, currently in clinical trials. NGM's R&D Day is scheduled for December 9, 2020, to showcase its pipeline, which addresses various diseases, including cancer.
FAQ
What is the market cap of NGM Biopharmaceuticals (NGM)?
What does NGM Biopharmaceuticals focus on?
What is the ALPINE 4 trial?
What recent strategic shift did NGM Bio announce?
What is the significance of the NGM Bio and Atlas Neon Parent, Inc. merger?
How is NGM Bio leveraging AI and machine learning?
What are some key highlights from NGM Bio’s recent financial report?
What are the main therapeutic areas NGM Bio is targeting?
What are some NGM Bio products currently in development?
What is NGM Bio's approach to drug discovery?
How can investors access more information about NGM Bio?
